How Is PolyNovo (ASX:PNV) Expanding Its NovoSorb Platform Beyond Burns?

Sonal Goyal

05 November 2026 06:16 PM AEDT

How Is PolyNovo (ASX:PNV) Expanding Its NovoSorb Platform Beyond Burns?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Commercial sales increased 16.7% to A$138.4 million (21.3% at constant currency), with growth across all regions.

• PolyNovo achieved positive EBITDA of A$12.1 million and net profit after tax of A$7.3 million.

• The company's new Manufacturing Facility construction was completed, with validation activities progressing ahead of FY27 transition.

Shares of PolyNovo Ltd (ASX:PNV) closed at A$0.905 on 05 November 2026, gaining 3.43% during the session. The S&P/ASX 200 (XJO) rose 2.61%, adding 230.60 points to 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, gaining 1,240.30 points to 35,329.10. Overnight Wall Street gains, following Democrats' decisive victory in the U.S. midterm elections, supported the broader market rally. PolyNovo is a leading medical technology company headquartered in Melbourne, specialising in the management of complex wounds through its proprietary NovoSorb polymer technology.

FY26 Financial Results

On 26 August 2026, PolyNovo announced its financial results for the year ended 30 June 2026. Total Revenue increased 16.1% to A$150.0 million, with commercial sales rising 16.7% to A$138.4 million, or 21.3% at constant currency. The company reported positive EBITDA of A$12.1 million, up 8.1%, while underlying EBITDA reached A$13.4 million, up 50.4%. Net profit after tax was A$7.3 million, lower than the prior year's A$13.2 million, which had included a tax benefit of A$5.7 million and certain non-recurring items. Gross Margin was 89.0%, compared with 95.6% in the prior period, reflecting changes in inventories of finished goods.

Regional Growth and Clinical Expansion

Growth was delivered across all regions. The Americas contributed A$104.1 million in sales, up 14.7% (20.2% at constant currency), EMEA delivered A$20.6 million, up 17.3%, and APAC reached A$13.7 million, up 33.6% (37.8% at constant currency). Growth in indications outside burns in the US has delivered a compound annual growth rate of 52.8% over the past three years, signalling expanding clinical adoption of NovoSorb beyond its original burns application. The NovoSorb MTX commercial rollout progressed during the year, validating the broader potential of the platform.

Manufacturing and Regulatory Progress

Construction of PolyNovo's new manufacturing facility was completed during FY26, with validation activities progressing ahead of the planned FY27 transition. Manufacturing output increased materially in the second half, supporting improved operational efficiency and future growth capacity. On the regulatory front, PMA submission activities advanced, supporting future reimbursement and market expansion in the United States. Key BARDA-supported clinical trial milestones were also completed during the year.

About PolyNovo

PolyNovo Ltd is an ASX-listed medical technology company that develops and commercialises advanced wound care products based on its proprietary NovoSorb biodegradable polymer platform. The company's products are used in the treatment of burns and complex wounds, with clinical adoption expanding into broader wound care indications. PolyNovo has international operations in the United States, United Kingdom, India, Hong Kong and Singapore, with additional markets supported by distribution partners.

Sector Context

The ASX healthcare sector gained on 05 November 2026, with the Health Care sub-index rising 3.64%. Medical technology companies with differentiated product platforms continued to attract attention, particularly those expanding their clinical evidence base and addressing unmet needs in wound care and surgical settings. Globally, wound care markets remain supported by ageing populations and increasing prevalence of chronic and complex wounds.

Risks

Key risks include execution risk around the PMA submission and approval process in the United States, which is critical for expanded reimbursement and market access. Foreign currency movements, particularly AUD/USD, affect reported sales given the Americas are the largest revenue contributor. The transition to the new manufacturing facility introduces operational risk during validation and ramp-up. Competition from established wound care and skin substitute providers remains a factor. The lower gross margin in FY26, driven by inventory changes, is also a metric to monitor.

Catalysts on Watch

Near-term catalysts include the PMA submission outcome and any resulting expanded US reimbursement, the transition to the new manufacturing facility, continued expansion of NovoSorb MTX adoption, further clinical evidence publication supporting indications beyond burns, the appointment of a Chief Scientific Officer and the establishment of a Business development function to explore partnerships and licensing opportunities.

The Path Forward

PolyNovo's FY26 result reflected continued commercial sales growth across all regions, with expanding adoption of its NovoSorb platform beyond burns. The company enters FY27 with a new manufacturing facility, an advancing PMA submission and a broadening product portfolio. The pace of NovoSorb MTX adoption and the US regulatory pathway will be pivotal to the company's next phase of growth.

FAQs

Q: What were PolyNovo's FY26 commercial sales?

A: Commercial sales reached A$138.4 million, up 16.7% year-over-year (21.3% at constant currency).

Q: Is PolyNovo profitable?

A: Yes, the company reported FY26 EBITDA of A$12.1 million and net profit after tax of A$7.3 million.

Q: What is NovoSorb MTX?

A: NovoSorb MTX is an extension of PolyNovo's NovoSorb polymer platform, expanding its application into broader wound care indications beyond burns.

Q: What is PolyNovo's largest revenue region?

A: The Americas is the largest region, contributing A$104.1 million or approximately 75% of commercial sales in FY26.

Q: What regulatory milestone is PolyNovo pursuing in the US?

A: The company is advancing a PMA (Premarket Approval) submission to support expanded reimbursement and market access in the United States.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.